CAG方案治疗中高危骨髓增生异常综合征的临床观察  

Treatment outcome of CAG regimen for the intermediate and high risk myelodysplastic syndrome

作　　者：隋潇徽[1] 周慧[1] 刘新[1] 李颖[1] 王欣[1] 许洪志[1] 

机构地区：[1]山东大学附属山东省立医院血液科,山东济南250021

出　　处：《中华肿瘤防治杂志》2008年第21期1666-1668,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:观察CAG方案(阿糖胞苷+阿柔比星+粒细胞集落刺激因子)治疗中高危骨髓增生异常综合征(MDS)的临床疗效及主要不良反应。方法:应用CAG方案治疗中高危MDS 17例。1个周期后评价疗效,有效者继续接受1个周期治疗,缓解后治疗采用CAG方案与常规化疗交替。结果:17例患者中,完全缓解(CR)6例,部分缓解(PR)5例,骨髓完全缓解(MCR)伴血液学进步(HI)5例,未缓解(NR)1例。有效率94.12%,完全缓解率35.30%。6例进展为急性髓系白血病(AML),中位总时间为10.5个月(6～16个月)。中位死亡时间17个月(10～22个月),1年总生存率88.24%,2年总生存率69.33%。主要的不良反应为骨髓抑制(15/17)。结论:CAG方案治疗中高危MDS安全有效,长期疗效仍需进一步观察。OBJECTIVE： To observe the efficacy and adverse events of treatment for the intermediate and high risk myelodysplastic syndrome （MDS） with CAG regimen. METHODS： Seventeen patients were included, the outcome was evaluated after 1 course of treatment. The responders continued to receive another course of treatment , and received CAG regimen or intensive chemotherapy altermative for post-remission therapy. RESULTS： Six cases achieved completely remission（CR）, 5 cases achieved partial remission （PR）, 5 cases achieved bone marrow completely remission （MCR） and hematologic improvement （HI） ,only 1 case none remission （NR）. CAG regimen achieved a CR rate of 35.30% and RR rate of 94.12%. Six cases progressed to AML, and the median time was 10.5 months. The median time of death was 17 months. The overall survival rates were 88.24% at 1 year and 69. 330% at 2 years. CONCLUSION： CAG regimen for middle and high risk MDS is effective. Longterm outcome needs to be observed further.

关 键 词：骨髓增生异常综合征/药物疗法 阿柔比星/治疗应用 阿糖胞苷/治疗应用 治疗效果 

分 类 号：R55[医药卫生—血液循环系统疾病]